Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

• Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Recruitment ended
  2023-509047-26-00 1 2024-06-13

Showing 1–1 of 1 trials